Trapax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trapax

This overview defines the identity, composition, and general purpose of Trapax (Lorazepam), strictly adhering to factual accuracy and excluding specific usage instructions or safety information.

Quick Facts: Trapax (Lorazepam)

Property Description
Active Ingredient Lorazepam (INN)
Forms Oral tablets, oral solution, solution for injection
Pharmacological Class Benzodiazepine; Central Nervous System (CNS) Depressant
General Purpose Relieves acute anxiety, induces sedation and relaxation
Origin Synthetic compound

Lorazepam: Definition and Pharmacological Type

Trapax is a trade name for the pharmaceutical substance Lorazepam, which belongs to the class of benzodiazepine medicines and acts as a Central Nervous System (CNS) depressant. Lorazepam is a fully synthetic compound defined by its international nonproprietary name (INN). Its classification as a benzodiazepine is globally recognized and is characterized by its interaction with the central nervous system. This profile means the medication is clinically recognized for its ability to reduce excessive alertness and promote emotional tranquility. The drug's intermediate-acting duration distinguishes it from both very short-acting and long-acting agents in its class, positioning it for effective management of acute, time-sensitive states of distress.


Composition, Forms, and General Purpose

Lorazepam is a single-ingredient product available in oral tablets, oral solutions, and parenteral (injectable) formulations, which provides flexibility in urgent and routine care scenarios. The composition consists of the active ingredient plus standard pharmaceutical excipients for solid forms, while the injectable formulations are suspended in a specialized aqueous or hydroalcoholic vehicle. The availability of the injectable form is a significant differentiating factor, allowing for swift and controlled administration when a patient requires immediate sedation, such as prior to minor surgical or diagnostic procedures. The drug’s general purpose is achieved by enhancing the inhibitory effects of the GABA neurotransmitter. Lorazepam is frequently utilized to manage acute anxiety and provide fast-acting sedation, achieving prompt emotional tranquility and physical relaxation.

What side effects are possible with Trapax?

Possible Side Effects and Safety Information

Trapax, which contains the active substance Lorazepam, is officially documented to possess a safety profile primarily defined by its effects on the Central Nervous System (CNS). Adverse reactions are grouped by frequency and affected body system as classified in regulatory documents.

The most frequent adverse reactions, classified as Very Common, include sedation, drowsiness, dizziness, and unsteadiness (ataxia). These CNS depressant effects are often more pronounced at the start of treatment.

Frequency Classification Documented Examples
Very Common Sedation, Drowsiness, Dizziness, Ataxia
Common Confusion, Fatigue, Muscle weakness
Uncommon Nausea, Skin reactions, Change in libido

Official labeling lists Serious Adverse Reactions, which include respiratory depression (especially when co-administered with other CNS depressants like opioids), coma, and life-threatening acute withdrawal reactions following abrupt discontinuation after prolonged use. Use of Lorazepam is contraindicated in patients with acute narrow-angle glaucoma.

The risk of developing physical and psychological dependence is a duration-related pattern explicitly noted in regulatory documents, increasing with longer treatment duration and higher daily doses. Specific safety considerations are noted for special populations: older adults may be more susceptible to sedative effects, increasing the risk of confusion and falls. Caution is also required for patients with severe hepatic impairment, as use may worsen hepatic encephalopathy.

Overdose and Emergency Response

An overdose of Trapax (which contains alprazolam) can depress the central nervous system, leading to symptoms that range from severe drowsiness to life-threatening complications. Because alprazolam is a benzodiazepine, an overdose, especially when combined with other central nervous system depressants like alcohol or opioids, can significantly slow or stop breathing.

Symptoms of Overdose

Symptoms may include:

  • Profound drowsiness, confusion, and disorientation
  • Loss of coordination (ataxia) or impaired motor function
  • Slurred speech
  • Significantly slowed or shallow breathing
  • Low blood pressure
  • Loss of consciousness or coma

When to Seek Immediate Help

Trapax overdose is a medical emergency. You must seek professional medical help immediately if you or someone else has taken more than the prescribed dose or is exhibiting any signs of an overdose. The immediate goal of treatment is supportive care, focusing on maintaining breathing and vital signs. A specific benzodiazepine antagonist, flumazenil, may be administered in a hospital setting to reverse the effects, although its use is reserved for specific clinical situations due to potential risks, such as inducing seizures. It is vital to inform emergency personnel of all substances ingested, including alcohol or other medications.

Therapeutic Uses of Trapax

Lorazepam (Trapax) is generally used across conditions presenting with acute episodes where symptoms of central nervous system (CNS) over-excitation create distress or functional impairment. Its use is primarily indicated for these domains where short-term symptomatic assistance is needed.

What Trapax Treats: Main Uses and Benefits

Lorazepam is commonly used to help with a range of conditions, including anxiety disorders, emergency management of status epilepticus (continuous seizures), managing symptoms of alcohol withdrawal syndrome, and as premedication before surgery. In clinical scenarios, it is applied in contexts marked by temporary physiological imbalance.

“This medication is considered relevant for easing symptoms that become temporarily overwhelming, offering supportive relief to patients during difficult episodes.”

It is applied when patients experience pronounced symptoms of severe emotional tension, panic, agitation, or neurological instability. It provides support that helps ease the overall symptom burden and may assist with supporting functional stability during periods of heightened discomfort.

Quick Fact: Relief for Acute Distress Domain Symptom Types Patient Benefit
Anxiolysis Panic, intense tension, pathological worry Supports emotional comfort
Crisis Care Continuous seizures, severe agitation Assists with symptomatic stability
Supportive Withdrawal tremors, pre-procedure apprehension May assist with relaxation and calm

Regulatory References

  1. National Library of Medicine (NIH) DailyMed database

Eligibility and Restrictions for Use

This section summarizes the official eligibility information for Trapax (Lorazepam) as defined by government regulatory documents, such as those from the FDA and EMA.

Contraindicated Populations

Use of Trapax is strictly forbidden (contraindicated) for individuals with:

  • Known hypersensitivity or allergy to lorazepam, other benzodiazepines, or any component of the formulation.
  • Acute narrow-angle glaucoma.

Populations Requiring Restricted Use

Use requires special consideration and caution from a healthcare provider in patients with:

  • Severe hepatic insufficiency or encephalopathy.
  • Compromised respiratory function, such as COPD or sleep apnea syndrome.
  • A history of alcohol or drug abuse, due to the heightened risk of dependence.
  • Primary depressive disorder or psychosis (not recommended for use as sole therapy).
  • Elderly or debilitated patients, due to increased sensitivity to sedative effects.

Age and Life Stage Eligibility

  • Pediatric Use: Safety and effectiveness have not been established for children under 12 years of age for anxiety management.
  • Pregnancy: Use is generally not recommended as the drug crosses the placenta and carries a documented risk of neonatal withdrawal syndrome with chronic use near term.
  • Lactation (Breastfeeding): Passes into breast milk; monitoring the infant for sedation is necessary, and use is generally advised with caution or not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Lorazepam (Trapax) as stipulated in government regulatory labeling, focusing strictly on required constraints and prohibitions.

Pharmacodynamic Interactions and Restrictions

Co-administration with other Central Nervous System (CNS) depressants results in a pharmacodynamic reinforcement of effects. This documented interaction increases the risk of outcomes like profound sedation and respiratory depression. The combination of Lorazepam with opioids carries an explicit regulatory boxed warning, specifying that co-administration must be reserved for cases where alternative treatments are inadequate. The regulatory label also stipulates that concurrent use with alcohol (ethanol) is prohibited due to the risk of increased CNS-depressant effects. Other substances causing this additive effect include barbiturates, antipsychotics, sedative/hypnotics, antidepressants, and anticonvulsants.

Metabolic and Exposure-Altering Interactions

Lorazepam is primarily metabolized via glucuronidation. Agents that inhibit this pathway cause a pharmacokinetic interaction that alters drug exposure. Both valproate and probenecid are documented to reduce the clearance and increase the plasma concentrations of Lorazepam. The official regulatory requirement specifies that the Lorazepam dosage must be reduced by approximately 50% when co-administered with either of these two agents. There are no mandatory timing requirements or prohibitions documented for general food products.

Population-Specific Notes

Official labeling notes that elderly or debilitated patients may be more susceptible to sedative effects, which compounds the risk associated with interactions. Caution is also required in cases of severe hepatic insufficiency, as Lorazepam may officially worsen hepatic encephalopathy.

Mechanism of Action

Trapax (lorazepam) is a benzodiazepine that acts within the central nervous system to influence neuronal signaling. Its core mechanism involves increasing the signaling of the major inhibitory neurotransmitter, gamma-aminobutyric acid (GABA).


Positive Allosteric Modulation of GABA-A Receptors

Trapax engages mechanisms by binding to a specific allosteric site on the GABA-A receptor complex, which is distinct from the binding site of the natural ligand, GABA. This interaction increases the receptor's affinity for GABA, thereby influencing processes mediated by distinct signaling patterns.


Increasing Inhibitory Neurotransmission

This modification increases the overall inhibitory effect of GABA. When GABA binds, the receptor opens its associated chloride ion channel more frequently, allowing a greater influx of negatively charged chloride ions ( Cl^-) into the neuron. This molecular consequence leads to hyperpolarization (making the neuronal membrane potential more negative), which reduces the magnitude of excessive mediator activity and contributes to a reduction in neuronal excitability throughout the central nervous system.

Dosage and Administration Information

Lorazepam is administered through three principal approved routes: oral (using tablets or solution), intramuscular (IM), and intravenous (IV) injection. The parenteral routes are typically reserved for rapid, acute intervention and pre-procedural sedation, while oral forms are used for routine administration.

The medicine is generally intended for short-term use, typically limited to two to four weeks. Official guidelines mandate that discontinuation requires a gradual dosage reduction (tapering).

Context of Use Typical Adult Dose (Official Range) Frequency/Schedule
Routine Oral Administration Initial 2 mg to 3 mg daily; maintenance 2 mg to 6 mg daily. Divided doses, usually 2 to 3 times per day.
Status Epilepticus (IV) 4 mg single dose, administered slowly. Intermittent, may be repeated once after 10-15 minutes.
Premedication (IM/IV) Single dose of 2 mg to 4 mg. Administered once prior to the procedure.

Specific procedural requirements govern administration. The IV solution must be diluted with an equal volume of a compatible diluent prior to injection, and the maximum rate of IV injection must not exceed 2 mg/ minute. Oral tablets may be taken with or without food. Official instructions require a lower initial dose for older or debilitated patients and those with hepatic or renal impairment to account for potential sensitivity.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trapax

Research Evidence for Major Depressive Disorder (MDD)

The research available for Trapax in Major Depressive Disorder (MDD) primarily consists of short-term Randomized Controlled Trials (RCTs) and analyses that look across the findings of these trials. These studies were used in research exploring how symptoms change over time in adult patients diagnosed with MDD. Researchers monitored outcomes related to symptom intensity, using standardized scales to measure changes in depressive severity, and tracked patients who met criteria for a defined response or remission.

These short-term studies reported measurements on how symptoms changed in the observed populations during the study period, typically lasting around six to eight weeks. Reported outcomes were limited to these acute timeframes. Reported data on tolerability detailed the occurrence and types of observed adverse events within the study populations.

Long-term outcomes and sustained effects beyond the intermediate observation window are not fully established, as follow-up durations were limited in the primary research. Evidence remains limited or insufficient for certain groups, such as older adults or adolescents. Results apply only to the specific populations studied.

Research Evidence for Generalized Anxiety Disorder (GAD)

Research for Trapax in Generalized Anxiety Disorder (GAD) has mainly involved short-term RCTs. The studies examined outcomes related to physical discomfort and measured changes in episodic or acute anxiety severity. The studies tracked changes over defined time intervals, typically lasting 8 to 10 weeks. Research highlights changes measured during these short study periods, and studies report how anxiety levels evolved in the observed populations.

Outcomes regarding the maintenance of symptom change and the risk of symptoms returning over periods longer than 10 weeks are not fully described. This means that data are still emerging for sustained changes and for tracking the recurrence of symptoms over time.

Research Evidence for Panic Disorder (PD)

The evidence base for Trapax in Panic Disorder (PD) has been evaluated in short-term RCTs. Research examined outcomes capturing phases of heightened symptom activity, such as measuring the change in the reported frequency of panic attacks and the related severity of anticipatory anxiety. Findings were often based on modest sample sizes and relied partly on patient-reported outcomes describing perceived discomfort. Certainty remains low due to modest sample sizes and limited follow-up durations.

What Remains Unclear or Requires More Research

A primary limitation across the entire evidence base is that the follow-up durations were limited, meaning long-term effects are not fully established. Comparative evidence against other non-medicinal approaches is sometimes lacking. Subgroup findings are uncertain for less-studied populations, and research highlights that many critical aspects—especially concerning the durability of response and sustained change in daily functioning over extended periods—are not fully established.

Key Studies & References

  1. Generalised anxiety disorder and panic disorder in adults: management (NICE Guideline CG113)
  2. Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis of Double-Blind Randomized Controlled Trials
  3. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder

Frequently Asked Questions (FAQ)

Common questions about Trapax (FAQ)


Q: What is Trapax used for besides the main conditions listed by the doctor?

Official regulatory documents define specific approved uses (known as indications) for Trapax, such as relieving acute anxiety and inducing sedation before medical procedures. Information provided in official drug labeling is restricted to these authorized uses. Any potential use outside of these documented indications is not covered by the regulatory label.


Q: Is Trapax the same kind of medicine as [Similar Drug Name 1]?

Trapax is the trade name for the substance lorazepam, which is classified as a benzodiazepine. This is a type of medicine known as a Central Nervous System (CNS) depressant, meaning it works by slowing down brain activity. Official labeling classifies medicines based on their pharmacological type.


Q: What should I do if I feel drowsy after taking Trapax?

Official safety information notes that the very common effect of drowsiness or sedation may impair mental alertness and physical coordination. Because of this potential effect, activities requiring concentration or quick reflexes may be affected.


Q: Why do some people stop taking Trapax soon after starting it?

Regulatory documents indicate that common adverse effects like drowsiness, dizziness, and unsteadiness are often more pronounced at the beginning of treatment. These initial effects can sometimes be a factor in the discontinuation of the medicine. Remember that official guidelines mandate a gradual dosage reduction when stopping use.


Q: Do studies suggest that Trapax works better for some people than others?

Research evidence summarized in official documents applies primarily to the specific populations studied in clinical trials. For certain patient groups, such as older adults or adolescents, official research regarding long-term outcomes remains limited or insufficient. This means that effects are not fully established across all populations.


Q: Can Trapax affect my ability to drive or operate machinery?

Yes, official labeling includes an explicit warning that Trapax may impair the mental and physical abilities needed for hazardous tasks. Due to its CNS depressant effects, the label states that patients should be warned against performing activities such as driving or operating heavy machinery.


Q: Why is Trapax sometimes prescribed for symptoms not listed in its main uses?

The information in official drug labeling is restricted to the specific uses, or indications, that have been authorized by regulatory agencies. The decision to use a medicine for any purpose is a professional clinical decision.


Q: What is the difference in purpose between Trapax and a typical antidepressant?

Trapax is a benzodiazepine that works by increasing the inhibitory effects of the GABA neurotransmitter in the brain. Due to its different mechanism and purpose, it is not recommended for use as a sole treatment for primary depressive disorders or psychosis, which are typically managed by other classes of medicines like antidepressants.


Q: Is it better to take Trapax in the morning or at night?

Regulatory documents indicate that routine oral administration is typically prescribed in divided doses throughout the day, usually two or three times daily. The specific timing is managed on an individual basis based on the condition being addressed.


Q: What is the risk of having a severe allergic reaction to Trapax?

Trapax is contraindicated (strictly forbidden) for anyone who has a known hypersensitivity or allergy to lorazepam or other benzodiazepines. Contraindication is the highest warning, meaning the risk of harm is considered too high to permit use in those individuals.


Q: How soon after starting Trapax can I expect the full effects to be noticeable?

The medicine is considered fast-acting for effects like acute sedation and relaxation, which may be felt shortly after taking a dose. However, the full, sustained changes in anxiety levels observed in regulatory clinical trials may take several weeks of use to become fully noticeable.


Q: What is the difference between Trapax and [Similar Drug Name 2] in terms of side effects?

The official safety profile for Trapax, as detailed in regulatory documents, is based exclusively on the adverse reactions documented for lorazepam. Comparisons between Trapax and other medicines are not provided in official regulatory labeling.


Q: What are the ingredients in Trapax besides the active drug?

Trapax contains the active drug lorazepam along with non-active ingredients (excipients) which are necessary components for the tablet or solution formulation. The complete list of both active and non-active ingredients can be found in the official Patient Information Leaflet provided with the medicine.


Q: Do regulatory bodies classify Trapax as a high-risk drug?

Trapax is officially classified as a Schedule IV controlled substance, which means that its use, prescribing, and distribution are strictly regulated by government agencies. Official documents also include specific warnings, such as a Boxed Warning regarding use with opioids, to highlight important safety information.


Q: Is the 'feeling of calm' from Trapax the same as being sedated?

Trapax’s intended effect is to promote emotional tranquility and physical relaxation by reducing excessive neuronal activity. Sedation and drowsiness, however, are listed as very common adverse reactions (side effects) and are often more pronounced than the intended feeling of calm.


Q: Does Trapax interact with common allergy medicines or decongestants?

Official documents warn against taking Trapax with any other substance that acts as a Central Nervous System (CNS) depressant. This is because the combination can lead to dangerously increased effects such as profound sedation and respiratory depression. Some common allergy medicines or decongestants can fall under this CNS depressant classification.


Q: If I miss a dose of Trapax, what happens?

Official patient information typically provides a general, non-directive factual statement regarding how to proceed if you realize a dose has been missed. This information is meant to provide general guidance only.


Q: Can Trapax cause weight gain, or is that a common myth?

According to official regulatory documents, weight gain is not listed as a documented adverse reaction in the common or very common frequency classifications. The adverse reactions reported are primarily related to effects on the central nervous system.


Q: Does Trapax have any known interaction with caffeine or energy drinks?

Official labeling states that there are no prohibitions documented for general food products, and caffeine is not listed as a specific interacting agent that requires dosage adjustment. The major interactions documented are with other medicines and alcohol.


Q: Does Trapax interact with common over-the-counter pain relievers?

Official regulatory labeling for Trapax does not list common over-the-counter (OTC) pain relievers, such as ibuprofen or acetaminophen, as documented interacting agents. The primary warnings are reserved for substances classified as Central Nervous System depressants.


Q: What is the typical duration of effect for a single dose of Trapax?

Lorazepam is classified as an intermediate-acting medicine within its class. The duration of the acute pharmacological effect for a single dose is officially described as generally lasting between six and twelve hours, depending on the reason for use.


Q: What does 'contraindication' mean in the context of Trapax?

A contraindication means that the use of the medicine is strictly forbidden under certain circumstances or for certain patient groups. The official medical view is that the potential risk of harm in a contraindicated person is considered to outweigh any potential benefit.


Q: Can Trapax affect my blood pressure or heart rate?

Regulatory documents note that Trapax can, in some patients, cause low blood pressure (hypotension). This effect is particularly noted in individuals receiving the injectable formulations.


How should Trapax be stored and disposed of?

Lorazepam (Trapax) tablets must be stored within strict conditions to maintain product stability and potency, and require specific security and disposal procedures as a Schedule IV controlled substance.


Required Storage

  • Temperature: Store at Controlled Room Temperature (20^circ to 25 C / 68^circ to 77 F). Avoid excessive heat and freezing.
  • Protection: Keep the container tightly closed and protect the medicine from light and excessive moisture.
  • Child Safety: This and all medications must be kept out of the reach and sight of children and secured in a safe place.

Official Disposal

  • Preferred Method: Use an authorized drug take-back program or mail-back envelope for unused or expired medication.
  • Alternative: If no take-back option is available, mix the medicine with an undesirable substance (such as dirt or used coffee grounds) and place the mixture in a sealed container before discarding it in the household trash. Do not flush the tablets unless specifically instructed. All personal information must be removed from the container before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trapax found in:

A-Z Index: